ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT01964196

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01964196
Other papers using this trial's data
  • Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Advances in therapy, 2019-06 DOI, PubMed 30953333, PMC6824366 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01964196. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-17 (actual); primary completion 2015-07-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-
Condition
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Intervention (Drug)
ASP1517
Intervention (Drug)
Placebo
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01964196
Content hash
dd3104a23ef49125a39fa90ed654724c37692807332568ad854341063c772ac1